9 Includes the exercise in full by the underwriters of their overallotment option to purchase up to 311,250 additional new ordinary shares in the form of 1.245 million additional ADSs at the IPO price. MorphoSys disclosed net proceeds in its May 3 conference call to discuss first quarter 2018 results.